GlassScriptPhysician profile
Vasty Adade
NPI 1760058069
$2,194.14
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $730 · 2023: $833 · 2024: $194 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.68 | 2021-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $319.28 | 2021-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $282.30 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Indivior INC. | $250.62 | 2023-2025 | Sublocade |
| Corium, LLC | $170.11 | 2023 | Azstarys |
| Alkermes, INC. | $125.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $109.05 | 2022-2023 | Rexulti |
| Tris Pharma INC | $94.09 | 2023-2025 | Dyanavel Xr |
| Orexo US, INC. | $92.01 | 2021-2023 | Zubsolv |
| Supernus Pharmaceuticals, INC. | $71.86 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $69.71 | 2021-2023 | Trintellix |
| Eisai INC. | $21.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasty Adade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.